Nilgun Kapucuoglu

Nilgun Kapucuoglu

Auto-generated profile, based on publicly available information

Nilgun Kapucuoglu

Department of Pathology, Koç University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Pathology - Research and Practice
Verified
Journal Article
Closed access
NKNilgun Kapucuoglu
Nilgun Kapucuoglu
FAFatma Aktepe
Fatma Aktepe
HKHakan Kaya
Hakan Kaya
SBSema Bircan
Sema Bircan
NKNermin Karahan
Nermin Karahan
MÇMetin Çiriş
Metin Çiriş

1 July 2008 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
NKN. Kapucuoglu
N. Kapucuoglu
DBD. Bulbul
D. Bulbul
GTG. Tulunay
G. Tulunay
MTM.A. Temel
M.A. Temel

1 January 2007
Verified
Journal Article
Closed access
NKN Karahan
N Karahan
MGM Güney
M Güney
SBS Baspinar
S Baspinar
BOB Oral
B Oral
NKN Kapucuoglu
N Kapucuoglu
TMT Mungan
T Mungan

22 August 2019 in Food Science & Nutrition
Verified
Journal Article
Open access
PDF file
NSNurhayat Ozkan Sevencan
Nurhayat Ozkan Sevencan
MIMehmet Isler
Mehmet Isler
FKFatma Nilgun Kapucuoglu
Fatma Nilgun Kapucuoglu
ASAltug Senol
Altug Senol
BKBurcak Kayhan
Burcak Kayhan
MKMuhammed Cem Kockar
Muhammed Cem Kockar
Evidence suggests that gut microbiota dysbiosis plays a critical role in the initiation and promotion of inflammatory bowel disease (IBD). Kefir is a fermented dairy product including yeast and bacterial species. We aimed to investigate the effect of kefir on trinitrobenzene sulfonic acid (TNBS)‐induced colitis in rats using two different doses. Fifty‐four Wistar rats were divided into six groups. For 14 days, the normal control and colitis control groups were given tap water, kefir10 control, kefir10 colitis, and kefir30 control, and the kefir30 colitis groups were given phosphate‐buffered saline containing 10% or 30% kefir, respectively, instead of tap water. Colitis was induced by intracolonically administrating TNBS in the colitis control, kefir10 colitis, and kefir30 colitis groups. On the 14th day, the rats were sacrificed. The weights and lengths of the colons were measured and macroscopically evaluated, and the distal 10 cm segments were subjected to a histopathological examination. The incidence of bloody stool and diarrhea in the kefir10 colitis group was found to be less than the colitis control and kefir30 colitis groups. The colonic weight/length ratio in the kefir10 colitis group was lower than that in the colitis control and kefir30 colitis groups. We detected that the 10% kefir treatment reduced TNBS‐induced macroscopic colonic damage, while it was exacerbated by the 30% kefir treatment. No significant difference was observed between the colitis groups in terms of microscopic colonic damage scoring. These results indicate that kefir, with a careful dose selection, may be a useful agent in the treatment of IBD.

1 September 2023 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
PBPınar Bulutay
Pınar Bulutay
ÖEÖzgür Can Eren
Özgür Can Eren
ÖÖÖzlem Özen
Özlem Özen
AHAsuman Nihan Haberal
Asuman Nihan Haberal
NKNilgün Kapucuoğlu
Nilgün Kapucuoğlu
Endocervical clear cell carcinoma (c-CCC) is a rare and HPV-independent adenocarcinoma type of cervix. Being usually resistant to conventional chemotherapy. Immunotherapy has recently been added as a preferred regimen as a second-line treatment option for programed cell death-ligand 1 (PD-L1)-positive or mismatch repair (MMR) deficient cervical carcinomas. In this study, clinicopathological features, PD-L1 expression, and MMR deficiency status of c-CCCs were investigated. Sixteen c-CCC diagnosed cases were included in this study. PD-L1 expression was evaluated using two different PD-L1 clones (22C3 and SP263). MMR deficiency status of the cases was evaluated using four MMR proteins (MLH1, PMS2, MSH2, and MSH6). Most of the c-CCC cases were presented as FIGO Stage I (68.75%). PD-L1 expression in either tumoral or tumor-infiltrating immune cells (TILs) was present in 62.5% (10/16) and 69% (11/16) of the 22C3 and SP263 clones, respectively. Most of the cases with high TIL density were also positive for PD-L1. The PD-L1 expression rate was less than 50% in most of the cases and 12.5% of the cases shared extensive PD-L1 staining. Overall, MMR deficiency was observed in 31.25% of the cases. Most of the MMR-deficient cases (80%) were PD-L1 positive. Although our study cohort is limited, we have shown that PD-L1 expression and MMR deficiency can be found in c-CCCs in variable degrees. These findings suggest that accompanying TIL density and MMR deficiency could be used as candidates for predicting PD-L1 positivity for c-CCCs. However, to indicate the clinical importance of these findings, objective treatment outcomes of cases treated with immunotherapy should be seen.

3 March 2025 in European Journal of Breast Health
Verified
Journal Article
Open access
AKAyşe Hümeyra Dur Karasayar
Ayşe Hümeyra Dur Karasayar
IKİbRahim Kulaç
İbRahim Kulaç
NKNilgün Kapucuoğlu
Nilgün Kapucuoğlu
Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine - European Journal of Breast Health